By comparison, depletion of FOXO1 by sgFOXO1 resulted in a marked delay in MCL progression and a survival benefit as evidenced by the diminished tumor burden and spleen enlargement (Supplemental Figure 7L), confirming that FOXO1 inhibition could suppress MCL progression in vivo. The gene discussed is FOXO1; the disease is neoplasm.